| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Limit of blank, limit of detection and limit of quantitation.
|
2008
|
3.57
|
|
2
|
Next-generation sequencing for cancer diagnostics: a practical perspective.
|
2011
|
2.31
|
|
3
|
Measurement of serum creatinine--current status and future goals.
|
2006
|
2.23
|
|
4
|
Magnesium metabolism and its disorders.
|
2003
|
2.00
|
|
5
|
Interferences in immunoassay.
|
2004
|
1.86
|
|
6
|
Biochemical markers of bone turnover: part I: biochemistry and variability.
|
2005
|
1.80
|
|
7
|
Phenylketonuria: an inborn error of phenylalanine metabolism.
|
2008
|
1.74
|
|
8
|
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334.
|
2009
|
1.70
|
|
9
|
Laboratory turnaround time.
|
2007
|
1.69
|
|
10
|
Reference materials and commutability.
|
2007
|
1.62
|
|
11
|
The case for common reference intervals.
|
2004
|
1.59
|
|
12
|
Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests.
|
2008
|
1.58
|
|
13
|
Insulin and insulin resistance.
|
2005
|
1.57
|
|
14
|
Standardisation of reference intervals: an Australasian view.
|
2007
|
1.50
|
|
15
|
Harmonising adult and paediatric reference intervals in australia and new zealand: an evidence-based approach for establishing a first panel of chemistry analytes.
|
2014
|
1.49
|
|
16
|
Evaluating assay precision.
|
2008
|
1.37
|
|
17
|
Familial hypercholesterolaemia.
|
2004
|
1.36
|
|
18
|
LC-MS/MS in the Clinical Laboratory - Where to From Here?
|
2011
|
1.36
|
|
19
|
Traceability, reference systems and result comparability.
|
2007
|
1.33
|
|
20
|
Drug testing in oral fluid.
|
2006
|
1.31
|
|
21
|
Uncertainty of measurement in quantitative medical testing: a laboratory implementation guide.
|
2004
|
1.28
|
|
22
|
Autocrine and paracrine actions of vitamin d.
|
2010
|
1.26
|
|
23
|
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists.
|
2010
|
1.24
|
|
24
|
Existing and Emerging Technologies for Point-of-Care Testing.
|
2014
|
1.21
|
|
25
|
Recommendations for lipid testing and reporting by Australian pathology laboratories.
|
2007
|
1.19
|
|
26
|
Colorectal cancer: molecular features and clinical opportunities.
|
2010
|
1.19
|
|
27
|
Results of an innovative education, training and quality assurance program for point-of-care HbA1c testing using the Bayer DCA 2000 in Australian Aboriginal Community Controlled Health Services.
|
2003
|
1.19
|
|
28
|
'Allowable Limits of Performance' for External Quality Assurance Programs - an Approach to Application of the Stockholm Criteria by the RCPA Quality Assurance Programs.
|
2012
|
1.17
|
|
29
|
Cystatin C--a paradigm of evidence based laboratory medicine.
|
2008
|
1.17
|
|
30
|
A practical approach to using mice in atherosclerosis research.
|
2004
|
1.16
|
|
31
|
The future of laboratory medicine: understanding the new pressures.
|
2004
|
1.16
|
|
32
|
Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation.
|
2009
|
1.15
|
|
33
|
Cultural and clinical effectiveness of the 'QAAMS' point-of-care testing model for diabetes management in Australian aboriginal medical services.
|
2006
|
1.15
|
|
34
|
From evidence to best practice in laboratory medicine.
|
2013
|
1.15
|
|
35
|
Evidence-based laboratory medicine: is it working in practice?
|
2012
|
1.15
|
|
36
|
Communication systems in healthcare.
|
2006
|
1.14
|
|
37
|
The de ritis ratio: the test of time.
|
2013
|
1.14
|
|
38
|
Trimethylaminuria: causes and diagnosis of a socially distressing condition.
|
2011
|
1.12
|
|
39
|
Quality indicators to detect pre-analytical errors in laboratory testing.
|
2012
|
1.12
|
|
40
|
HbA1c standardisation destination--global IFCC Standardisation. How, why, where and when--a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes.
|
2005
|
1.12
|
|
41
|
The Joint Committee for Traceability in Laboratory Medicine (JCTLM): a global approach to promote the standardisation of clinical laboratory test results.
|
2007
|
1.11
|
|
42
|
Reference intervals.
|
2008
|
1.10
|
|
43
|
The Australian pathology units and terminology standardisation project - an overview.
|
2012
|
1.10
|
|
44
|
Prerequisites for use of common reference intervals.
|
2007
|
1.10
|
|
45
|
The laboratory diagnosis of severe acute respiratory syndrome: emerging laboratory tests for an emerging pathogen.
|
2004
|
1.08
|
|
46
|
The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency.
|
2009
|
1.08
|
|
47
|
Methods of Estimating GFR - Different Equations Including CKD-EPI.
|
2011
|
1.06
|
|
48
|
Low level environmental lead exposure--a continuing challenge.
|
2008
|
1.06
|
|
49
|
Reference materials and reference measurement procedures: an overview from a national metrology institute.
|
2007
|
1.03
|
|
50
|
Assessing liver fibrosis with serum marker models.
|
2007
|
1.02
|